Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
MHLW Eyes Information Provisioning on Generic Supplies by Individual Brands
The Ministry of Health, Labor and Welfare (MHLW) will consider providing information on the available level of generic drugs on a brand-by-brand basis, rather than by API/specification, a senior official has said. Koichi Ando, director of the MHLW’s Economic Affairs…
To read the full story
Related Article
- FPMAJ Investigating Supply Status for 60% of All Drugs, Tally Due Out by Year-End
September 14, 2022
- Shipment Curbs Remain for Over 40% of Drugs Despite Sufficient Supply Volumes: FPMAJ Survey
June 24, 2022
- Shipment Curbs Lifted for Only 49 Products by End of 2021 after MHLW Request: FPMAJ Survey
March 25, 2022
- MHLW Publishes Brand-by-Brand Supply Status for 130 APIs Subject to Its Restriction Lifting Request
March 9, 2022
- Govt-Industry Arrangement for Drug Supply Survey Hits Rough Waters; FPMAJ Stands Pat on Continued Dialogue
February 10, 2022
- MHLW Calls for Lifting of Shipment Restrictions for 130 Generic API/Specifications after Survey Finds YOY Rise in Supplies
December 14, 2021
REGULATORY
- Officer Replacement Orders a “Last Resort” under PMD Act: MHLW Official
September 18, 2026
- Japan Panel Sees No Scientific Objection to Capvaxive NIP Addition
September 18, 2026
- Tavneos Blue Letter Action “Too Slow,” MHLW Panel Member Says
September 18, 2026
- Takaichi Tasks Ueno with Charting Growth Strategy for Drug Innovation
September 18, 2026
- Japan HIV, AIDS Cases Rise in H1 after 2025 Lows
September 18, 2026
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…